Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The Disease Activity Score in 28 joints (DAS28) is the standard composite index for quantifying rheumatoid arthritis disease activity in clinical practice and trials. It combines tender and swollen joint counts, an inflammatory marker (ESR or CRP), and the patient's global assessment into a single continuous score that drives treat-to-target decisions. Before escalating therapy, confirm the diagnosis meets ACR/EULAR RA Classification Criteria. In lupus patients presenting with inflammatory arthritis, compare findings against SLEDAI to distinguish RA from lupus arthropathy. Screen for cardiovascular risk with ASCVD Risk, since RA independently elevates cardiovascular risk, and check renal function with eGFR before starting methotrexate or NSAIDs.
Formula: DAS28-ESR = 0.56×√(TJC28) + 0.28×√(SJC28) + 0.70×ln(ESR) + 0.014×GH (VAS 0-100mm)
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The DAS28 examines 28 specific joints: bilateral shoulders, elbows, wrists, and knees (4 joints each), plus bilateral metacarpophalangeal (MCP) joints 1-5 and proximal interphalangeal (PIP) joints 1-5 (10 joints each side). Hips, ankles, and feet are deliberately excluded from the count — not because they're clinically unimportant, but because the original derivation cohort found they added little discriminative value and are harder to examine reliably. For each of the 28 joints, record whether it is tender to palpation (patient reports pain on pressure or joint-line stress) and separately whether it is swollen (visible or palpable synovial thickening, not just bony enlargement from osteoarthritis). A joint can be tender without swollen, swollen without tender, both, or neither. Sum the total tender joints (0-28) and total swollen joints (0-28) separately — these become two independent inputs into the formula, not a combined count. Consistency matters more than perfection: use the same examiner and same technique at each visit when tracking a patient over time, since inter-observer variability in joint counts is one of the largest sources of noise in DAS28 trending.
DAS28-ESR uses the erythrocyte sedimentation rate (mm/hr) drawn at or near the visit date — same-day or within a few days is standard practice, since ESR can fluctuate with intercurrent illness. A DAS28-CRP variant exists and correlates closely with the ESR version but uses a slightly different formula and generally reads a little lower; the two are not numerically interchangeable, so track a patient with the same variant longitudinally. The patient global health assessment is a 0-100mm visual analog scale (VAS) answering 'considering all the ways your arthritis affects you, how are you doing?' — 0 being 'very well' and 100 being 'very poor.' This captures the patient's subjective disease burden (pain, fatigue, function) that objective joint counts and lab values miss. Administer it consistently, ideally self-reported on paper or tablet before the clinician interview, to avoid anchoring the patient's answer to the discussion that follows.
The DAS28-ESR formula is: 0.56 × √(tender joint count) + 0.28 × √(swollen joint count) + 0.70 × ln(ESR) + 0.014 × (global health VAS). The square-root transformation of joint counts dampens the influence of very high counts, so going from 20 to 25 tender joints changes the score much less than going from 0 to 5. The natural log of ESR similarly compresses the effect of extreme inflammatory marker elevations. Interpret the result against four bands: remission (<2.6), low disease activity (2.6-3.2), moderate disease activity (>3.2-5.1), and high disease activity (>5.1). EULAR treat-to-target recommendations set remission or, at minimum, low disease activity as the goal for every RA patient, reassessed and acted on at least every 1-3 months until the target is reached. A change of ≥1.2 points is considered a clinically meaningful response to therapy, while a change of 0.6-1.2 is a moderate response — these thresholds (EULAR response criteria) are what most trials and treat-to-target protocols use to judge whether a DMARD change worked.
Rheumatologists and rheumatology nurse practitioners
Recalculate DAS28 at every visit (every 1-3 months during active treatment) to objectively decide whether to hold, escalate, or switch DMARD therapy. A score that plateaus above 3.2 despite adequate methotrexate dosing signals it's time to add a biologic or targeted synthetic DMARD rather than waiting for further clinical impression alone.
Rheumatologists managing insurance prior authorizations
Many payers require documented moderate-to-high disease activity (DAS28 >3.2 or >5.1) despite conventional DMARD failure before approving biologics or JAK inhibitors. A clearly calculated, dated DAS28 in the chart streamlines prior authorization and appeals.
Clinical research coordinators and trial investigators
RA trials commonly use DAS28 remission or EULAR response criteria as primary or secondary endpoints. Screening thresholds (often DAS28 >3.2 or >5.1 for enrollment) and serial follow-up scores are calculated identically to clinical practice, making this tool useful for trial site staff.
Rheumatology fellows and allied health teams
Standardizing the joint count and VAS collection process across a clinic (nurse collects VAS and vitals, fellow performs joint exam, attending reviews the calculated DAS28) creates a reproducible workflow that reduces variability between visits and providers.
Rheumatologists considering DMARD de-escalation
Before attempting a biologic taper or discontinuation in a patient who has been stable, confirm sustained DAS28 remission (<2.6) over multiple consecutive visits, since a single low reading can reflect measurement noise rather than true sustained remission.
Patients newly diagnosed with RA
Showing a patient their own DAS28 trend over time — falling from high to moderate to low activity — helps them understand that RA control is measurable and gives concrete meaning to 'the medication is working' beyond how their joints feel on a given day.
The CRP variant uses a different constant and generally produces a slightly lower numeric score than ESR for the same clinical picture. Track a given patient with the same variant every visit — switching between them mid-course can create the false appearance of improvement or worsening.
Because ankles and feet aren't included in the 28-joint count, a patient with severe, painful, treatment-refractory forefoot synovitis but quiet upper-limb and knee/wrist joints can score in remission on DAS28 while remaining clinically quite active. Always examine feet separately and don't let a low DAS28 override a clear clinical picture of active foot synovitis.
Concurrent fibromyalgia (present in roughly 15-25% of RA patients) drives up tender joint counts and global health VAS without corresponding swelling or elevated inflammatory markers, producing a falsely elevated DAS28. Weight the swollen joint count and objective inflammatory marker more heavily than tender count and VAS alone when fibromyalgia overlap is suspected, and avoid escalating biologic therapy based on tenderness/VAS-driven scores alone.
ESR can be falsely normal in RA — up to a third of patients with active synovitis have a normal ESR, particularly women, older patients, and those with lower muscle mass. If joint counts and clinical exam suggest active disease despite a low DAS28 driven by a normal ESR, trust the joint exam and consider a CRP-based recalculation.
A patient starting at DAS28 6.5 who drops to 3.8 has made a major clinically meaningful improvement (Δ>1.2) even though they're still in the moderate-activity band — don't dismiss the therapy as a failure just because the absolute score hasn't crossed into 'low.' Conversely, a patient stable at DAS28 3.0 for a year with no meaningful delta is a candidate for maintaining, not escalating, therapy.
Before attributing a high global health score entirely to joint inflammation, screen for comorbid depression, poor sleep, and central pain sensitization, all of which independently drive up the patient-reported VAS component and can mislead treat-to-target decisions if taken at face value.
The value of DAS28 as a treat-to-target tool depends on serial, protocolized measurement — ad hoc calculation only when a patient 'seems worse' introduces confirmation bias and misses the slow, gradual disease creep that a scheduled score would catch earlier.
Psoriatic arthritis has a distinct pattern of involvement (dactylitis, enthesitis, DIP joints, axial disease) that the 28-joint RA-derived count doesn't capture. Use disease-specific tools like the DAPSA or minimal disease activity criteria for PsA instead.
DAS28 scores are grouped into four bands that drive treat-to-target decisions: remission (<2.6), low disease activity (2.6-3.2), moderate disease activity (>3.2-5.1), and high disease activity (>5.1). EULAR guidelines recommend targeting remission or, when not achievable, sustained low disease activity, reassessing every 1-3 months and escalating therapy when the target isn't met.
Use DAS28 at every rheumatology visit for a patient with confirmed rheumatoid arthritis to objectively track disease activity, guide DMARD/biologic escalation or tapering decisions, and document treat-to-target progress for clinical and administrative purposes.
DAS28 excludes ankle and foot joints, can be falsely elevated by fibromyalgia overlap, is unreliable in patients on IL-6 pathway inhibitors (which suppress ESR/CRP independent of disease control), and was validated specifically for RA rather than other inflammatory arthropathies.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Score the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria across joints, serology, acute-phase reactants, and duration. ≥6/10 classifies definite RA.
OpenRheumatologyScore SLE disease activity with SLEDAI-2K across 24 weighted clinical and lab descriptors. Free lupus flare and treatment-response calculator.
OpenCardiologyCalculate 10-year ASCVD risk using current 2026 ACC/AHA Pooled Cohort Equations. Statin thresholds: <5% low, 5–7.5% borderline, ≥7.5% intermediate, ≥20% high.
OpenClinicalCalculate eGFR with the CKD-EPI 2021 race-free formula to estimate kidney function and CKD stage from serum creatinine, age, and sex.
Open